Linganisha mbinu
Pitia mbinu ulizochagua bega kwa bega; safu zinazotofautiana zinaangaziwa.
| Kielezo cha SCORAD (Kupima Ukali wa Ugonjwa wa Ngozi unaosababishwa na Mzio)× | EASI (Eczema Area and Severity Index)× | |
|---|---|---|
| Nyanja | Dermatolojia | Dermatolojia |
| Familia | Process / pipeline | Process / pipeline |
| Mwaka wa asili≠ | 1993 | 2001 |
| Mwanzilishi≠ | European Task Force on Atopic Dermatitis (ETFAD) | Hanifin JM, Thurston M |
| Aina | Clinician-rated | Clinician-rated |
| Chanzo asilia≠ | Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195(1):10-19. DOI ↗ | Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Experimental Dermatology. 2001;10(1):11-18. DOI ↗ |
| Majina mbadala | SCORAD Index | EASI Index |
| Zinazohusiana≠ | 3 | 2 |
| Muhtasari≠ | The SCORAD is a comprehensive clinician-administered tool for measuring the extent and severity of atopic dermatitis (eczema). Developed by the European Task Force on Atopic Dermatitis in 1993, it combines objective clinical assessment with subjective symptom reporting. It is the gold standard for atopic dermatitis severity in clinical trials and dermatology practice. | The EASI is a structured, clinician-administered tool for assessing the extent and intensity of atopic dermatitis across the body. Developed by Hanifin and colleagues in 2001, it divides the body into four regions with weighted area factors, ensuring proportional contribution to total score. EASI has become the primary objective severity measure in atopic dermatitis clinical trials and is recommended by international regulatory authorities (FDA, EMA). |
| ScholarGateSeti ya data ↗ |
|
|